Takeda Research invests in Xenon Pharmaceuticals

On September 12, 2006, Xenon Pharmaceuticals Inc., a privately held company engaged in developing novel small molecule therapies for select neurological, cardiovascular and metabolic diseases, announced that Takeda Research Investment, Inc. (TRI) had made a strategic equity investment of US$5 million in the Company. TRI and Xenon have also entered into an agreement where Takeda Pharmaceutical Company Limited, through TRI, receives a Right of First Negotiation to select atherosclerosis discoveries made by Xenon.

TRI is the corporate venture arm of Takeda Pharmaceutical Company Limited, a world-class pharmaceutical company and the largest in Japan.

Roger Kuypers and Iain Mant of Fasken Martineau advised TRI in this transaction.